1952 — Everest Medicines Share News
0.000.00%
Last trade - 00:00- HK$11.47bn
- HK$11.42bn
- CNY1.71bn
Brief: Everest Medicines's Wei Fu Ceases To Be Chairman
Brief: Everest Medicines Subscribes For 15.8 Million ADSS OF I-MAB For $30.9 Million
Brief: Everest Medicines Expands Strategic Investment In I-Mab
HK-listed Everest Medicines falls on discounted share sale
Brief: Everest Medicines To Place 22.6 Million New Shares At HK$69.70 Per Share
Brief: Everest Medicines Says Exec Director & CEO Not Disposed Of Any Shares
Brief: Everest Medicines Says NMPA Granted Full Approval For Nefecon
Brief: Everest Medicines Posts FY Net Income RMB -1,041.4 Million
Brief: Everest Medicines Says PwC Agreed To Resign As Auditors Of Co
Brief: Everest Medicines Says Taiwan Food And Drug Administration Approved Nefecon
Brief: Everest Medicines Says HY Net Loss RMB632.4 Mln
Brief: Everest Medicines Posts Net Loss For Year RMB844.5 Mln
Brief: Everest Medicines Says Voluntary Lock-Up Undertaking By Controlling Shareholder
Brief: Everest Medicines And Kezar Life Sciences Receive IND Approval From China NMPA For Palizade Trial In Lupus Nephritis
Brief: Everest Medicines And Providence Entered Deal
Brief: Everest Medicines Sees Total Revenue Ranging Between RMB124 Mln And RMB126 Mln For Year
China's Everest Medicines climbs as US FDA approves Nefecon capsules
Brief: Everest Medicines Says Licensing Partner Calliditas Therapeutics Announced U.S. FDA Approved Nefecon Delayed Release Capsules
Brief: Everest Medicines Says Approval Of New Drug Application In China